ME 609 clinical trials
Also written ME-609.
How each study uses ME 609 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ME-609
- 4
Studies by the year they started
4 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2006 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Medivir (4)
Studies
Open first, then newest update. How each study uses ME 609 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex LabialisCompletedPhase 3MedivirNCT00361881Written as ME-609
- Safety Study of ME-609 for Treatment of Herpes Simplex Labialis in AdolescentsCompletedPhase 3MedivirNCT00375570Written as ME-609
- Efficacy of Acyclovir in Combination With a Glucocorticosteroid on UV-Induced Herpes LabialisCompletedPhase 2MedivirNCT00736437Written as ME-609
- Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised PatientsCompletedPhase 3MedivirNCT00735761Written as ME-609